Basel, Switzerland, January 22, 2025 — The Mario Negri Institute for Pharmacological Research...
Nanomed Europe 2025 (NME25) was a landmark event in the field of nanomedicine, co-organized by the European Technology Platform on Nanomedicine (ETPN) and Nanomed Spain, which celebrated their 20th anniversary in Barcelona. This special edition brought together over 350 experts to explore the future of nanomedicine, with a focus on innovative drug delivery systems and RNA therapeutics.
As a Platinum member of ETPN, CATUG was proud to sponsor and participate in this unique gathering of leaders in nanotechnology, biotech, and pharmaceutical innovation.
What Is Nanomed Europe 2025 (NME25)?
Nanomed Europe 2025 (NME25) is Europe’s leading conference focused on nanomedicine and drug delivery. It serves as a platform for researchers, clinicians, startups, and industry stakeholders to share their projects and promote collaboration. This year’s edition held special significance as it marked two decades of coordinated effort to advance nanomedicine research and translation across Europe.
The Organizers: ETPN and Nanomed Spain
ETPN (European Technology Platform on Nanomedicine) is an industry-led initiative supported by the European Commission. Its mission is to accelerate the development and clinical adoption of nanomedicine technologies by fostering collaboration between academia, industry, and policy makers.
Nanomed Spain is the national network for nanomedicine in Spain, acting as a key driver for innovation, knowledge exchange, and public-private partnerships in the field.
Together, ETPN and Nanomed Spain organized NME25 not only to highlight recent scientific advances, but also to commemorate 20 years of collaboration and impact in nanomedicine across Europe.
Key Trends and Takeaways from NME25
Precision Drug Delivery with Advanced Nanomaterials
Lipid nanoparticles (LNPs), nanocrystals, and polymer-based systems were key topics at the event. Many presentations showcased innovative approaches to improving the specificity, stability, and bioavailability of therapeutic agents.
RNA-Based Therapeutics Gaining Ground
RNA continues to attract attention for its applications in vaccines, gene editing, and protein replacement. Its versatility and scalability make it a cornerstone of next-generation therapies.
CAR-T and Cell Therapies on the Rise
The conference also highlighted the growing momentum behind CAR-T and other cell therapies, which are showing promise beyond cancer treatment, particularly in autoimmune and rare diseases.
Organ-on-a-Chip for Early-Stage Validation
Organ-on-a-chip platforms emerged as a major trend, with many groups presenting data on their use as in vitro models for drug testing, helping reduce reliance on animal studies.
Talks about Nanomedicine and Drug Delivery
We were honored to hear from an outstanding roster of keynote speakers, including:
Their talks sparked thoughtful discussion on the future of therapeutic development and the role of nanomedicine in solving some of today’s toughest biomedical challenges.
Congratulations to ETPN, Nanomed Spain, and Alexandre Ceccaldi for organizing such a meaningful and forward-thinking event.
And thank you to our team, Cesare Di Nitto, Cristina Kim Xuan Nguyen, and Alejandra Carreira, for representing CATUG and engaging with partners across the field.
The Future of RNA and LNP Technologies
At CATUG, we specialize in DNA, RNA, and LNP technologies, helping researchers bring ideas to life from early discovery to GMP production. Our services span sequence optimization, LNP formulation, preclinical evaluation, and IND-grade analysis and manufacturing.
Whether you're working on RNA-based vaccines, gene editing, or advanced drug delivery, CATUG is your partner from concept to clinic.
Contact us to explore how we can support your next project.
